Alvise Sernicola ¹,Anna Colpo ²,Anca Irina Leahu ² and Mauro Alaibac ¹Medicina 2022, 58(10), 1398; https://doi.org/10.3390/medicina58101398

In the field of advanced melanoma, there is an urgent need to investigate novel approaches targeting specific components of the cancer–immunity cycle beyond immune checkpoint inhibitors. The authors reviewed the basic understanding of the role of neutrophils in cancer biology, and the latest clinical evidence supporting the correlation between cancer-associated neutrophils and the prognosis and response to the immunotherapy of advanced melanoma. Finally, they propose that granulocyte and monocyte apheresis, an emerging non-pharmacological treatment in current dermatology, could become an investigative treatment targeting melanoma-associated neutrophils which could be potentially used in combination with the usual immune checkpoint inhibitors.

https://www.mdpi.com/1648-9144/58/10/1398